A Comparative Analysis of the Utility of Nottingham Prognostic Index and Ki-67 in Selecting ER-positive HER2-negative Patients for Oncotype DX Testing
Clinical Breast Cancer · 2026
DOI: 10.1016/j.clbc.2026.02.008 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Anita Golash und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The Hillingdon Hospital NHS Foundation Trust, London, United Kingdom; Department of Breast Surgery, East Cheshire NHS T…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Breast Neoplasms, Ki-67 Antigen, Neoplasm Recurrence, Local. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The Oncotype DX Recurrence Score (RS), Nottingham Prognostic Index (NPI), and Ki-67 are commonly used tools to assess recurrence risk and guide adjuvant treatment decisions in early breast cancer. This study evaluated the relationship between NPI, Ki-67, and Oncotype DX RS, and explored whether NPI and Ki-67 may help contextualize patient selection for genomic testing. PATIENTS: Patients had ER-positive, HER2-negative breast cancer and were node-negative or had micrometastatic disease or 1 to 3 macrometastatic lymph nodes. METHODOLOGY: This retrospective observational study analyzed five years of breast cancer data from East Cheshire. Associations between NPI, Ki-67, and Oncotype DX RS were assessed using correlation analysis. Chemotherapy recommendations based on NPI, Ki-67, and Oncotype DX RS were compared. Statistical significance was defined as P < .05. RESULTS: Among 195 patients (mean age 58.7 ± 9.4 years), chemotherapy was recommended in 62 (31.8%) based on Oncotype DX RS, with 52 (26.7%) ultimately receiving treatment. Ki-67 demonstrated a moderate correlation with Oncotype DX RS (r = 0.463, P < .001), while NPI showed a weaker but statistically significant correlation (r = 0.232, P = .001). Concordance with Oncotype DX RS was modest for both markers (51.8% for Ki-67 and 44.6% for NPI), indicating substantial discordance. CONCLUSION: NPI, using a threshold of 3.4 as recommended by NICE, may assist in identifying patients for whom Oncotype DX testing could be considered. Ki-67 may provide additional prognostic context when interpreted alongside NPI. These markers may contribute to broader risk stratification frameworks but should be viewed as complementary to genomic testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, The Hillingdon Hospital NHS Foundation Trust, London, United Kingdom; Department of Breast Surgery, East Cheshire NHS Trust, Macclesfield, United Kingdom. Electronic address: Anita.Golash@n…
- Department of Breast Surgery, East Cheshire NHS Trust, Macclesfield, United Kingdom.
- Department of Breast Oncology, East Cheshire NHS Trust, Macclesfield, United Kingdom.
- Department of Breast Oncology, East Cheshire NHS Trust, Macclesfield, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom.
Zitieren
APA
Golash, A., Roshanlall, C., Kokan, J., Clay, V., Khan, M., & Wilson, C. (2026). A Comparative Analysis of the Utility of Nottingham Prognostic Index and Ki-67 in Selecting ER-positive HER2-negative Patients for Oncotype DX Testing. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.02.008
Vancouver
Golash A, Roshanlall C, Kokan J, Clay V, Khan M, Wilson C. A Comparative Analysis of the Utility of Nottingham Prognostic Index and Ki-67 in Selecting ER-positive HER2-negative Patients for Oncotype DX Testing. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2026.02.008
BibTeX
@article{Golash2026,
author = {Golash, Anita and Roshanlall, Chandeena and Kokan, Jalal and Clay, Vanessa and Khan, Maryam and Wilson, Caroline},
title = {A Comparative Analysis of the Utility of Nottingham Prognostic Index and Ki-67 in Selecting ER-positive HER2-negative Patients for Oncotype DX Testing},
journal = {Clinical Breast Cancer},
year = {2026},
doi = {10.1016/j.clbc.2026.02.008}
}
EUVIMED